The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual ...

The Biden administration has proposed a new rule that could significantly expand Medicare and Medicaid coverage for obesity ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

A MAJOR warning has been issued by health bosses over the “dangerous risks” of “fake Ozempic” for sale online. The Health ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Strata Decision Technology data finds the number of bariatric surgeries in the Chicago area may have fallen by more than half ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

However, the drugs have their limits -- such as weight-loss plateaus and weight regain after stopping treatment -- and as ...